GB1565205A - Creation of Inventions and Patents with Artificial Intelligence

GB1565205A – Heterocyclic sulphoxides
– Google Patents

GB1565205A – Heterocyclic sulphoxides
– Google Patents
Heterocyclic sulphoxides

Download PDF
Info

Publication number
GB1565205A

GB1565205A
GB31969/75A
GB3196975A
GB1565205A
GB 1565205 A
GB1565205 A
GB 1565205A
GB 31969/75 A
GB31969/75 A
GB 31969/75A
GB 3196975 A
GB3196975 A
GB 3196975A
GB 1565205 A
GB1565205 A
GB 1565205A
Authority
GB
United Kingdom
Prior art keywords
formula
compounds
het
histamine
nitro
Prior art date
1975-07-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
GB31969/75A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Smith Kline and French Laboratories Ltd

Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1975-07-31
Filing date
1975-07-31
Publication date
1980-04-16

1975-07-31
Application filed by Smith Kline and French Laboratories Ltd
filed
Critical
Smith Kline and French Laboratories Ltd

1975-07-31
Priority to GB31969/75A
priority
Critical
patent/GB1565205A/en

1976-06-28
Priority to ZA763837A
priority
patent/ZA763837B/en

1976-07-05
Priority to IN1187/CAL/76A
priority
patent/IN146152B/en

1976-07-13
Priority to DK316076A
priority
patent/DK316076A/en

1976-07-13
Priority to US05/704,871
priority
patent/US4038408A/en

1976-07-21
Priority to CS764840A
priority
patent/CS203102B2/en

1976-07-22
Priority to CA257,550A
priority
patent/CA1069904A/en

1976-07-23
Priority to ZM97/76A
priority
patent/ZM9776A1/en

1976-07-23
Priority to BE169227A
priority
patent/BE844503R/en

1976-07-27
Priority to GR51357A
priority
patent/GR60853B7/en

1976-07-27
Priority to FR7622849A
priority
patent/FR2361881A2/en

1976-07-27
Priority to SE7608476A
priority
patent/SE7608476L/en

1976-07-29
Priority to LU75493A
priority
patent/LU75493A1/xx

1976-07-29
Priority to DD194123A
priority
patent/DD126081A5/xx

1976-07-30
Priority to CH978476A
priority
patent/CH609683A5/xx

1976-07-30
Priority to BG7633886A
priority
patent/BG27361A3/en

1976-07-30
Priority to ES450318A
priority
patent/ES450318A2/en

1976-07-30
Priority to NO762660A
priority
patent/NO762660L/no

1976-07-30
Priority to FI762192A
priority
patent/FI762192A/fi

1976-07-30
Priority to SU762386216A
priority
patent/SU618044A3/en

1976-07-30
Priority to DE19762634432
priority
patent/DE2634432A1/en

1976-07-30
Priority to NL7608491A
priority
patent/NL7608491A/en

1976-07-30
Priority to JP51092244A
priority
patent/JPS5219662A/en

1976-07-30
Priority to AR264158A
priority
patent/AR216056A1/en

1976-07-30
Priority to HU76SI1530A
priority
patent/HU173928B/en

1976-07-30
Priority to PL19153576A
priority
patent/PL191535A1/en

1976-07-30
Priority to AU16454/76A
priority
patent/AU1645476A/en

1976-07-31
Priority to OA55902A
priority
patent/OA05404A/en

1976-07-31
Priority to RO87166A
priority
patent/RO70855B/en

1977-04-13
Priority to US05/787,245
priority
patent/US4105770A/en

1980-04-16
Publication of GB1565205A
publication
Critical
patent/GB1565205A/en

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings

C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings

C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members

C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

C07D277/26—Radicals substituted by sulfur atoms

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P37/00—Drugs for immunological or allergic disorders

A61P37/08—Antiallergic agents

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P9/00—Drugs for disorders of the cardiovascular system

Description

PATENT SPECIFICATION ( 11) 1 565 205 m) ( 21) Application No 31969/75 (
22) Filed 31 Jul1975 ( 19), ( 61) Patent of Addition To No 1421999 dated 7 Feb 1974,
( 23) Complete Specification Filed 26 Oct 1976
Q ( 44) Complete Specification Published 16 Apr 1980
In ( 51) INT CL 3 C 07 D 213/24 A 61 K 31/395 C 07 D 233/64 275/02 277/22 ( 52) Index at Acceptance C 2 C 1380 1382 1410 1530 200 215 246 247 250 251 252 256 25 Y 28 X 30 Y 313 314 31 Y 320 322 326 32 Y 332 337 364 365 36 Y 373 37 Y 380 397 612 630 650 703 747 750 754 75 X 76 X 78 Y 802 80 Y AA RH RM SM ( 72) Inventors: GRAHAM JOHN DURANT CHARON ROBIN GANELLIN GEORGE RAYMOND WHITE TORBEN HESSELBO ( 54) HETEROCYCLIC SULPHOXIDES ( 71) We SMITH KLINE & FRENCH LABORATORIES LIMITED of Mundells, Welwyn Garden City, Hertfordshire, a British company do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:
This invention relates to pharmacologically active compounds, to methods for preparing 5 these compounds, and to pharmaceutical compositions containing these compounds The compounds of the invention can exist as acid addition salts but, for convenience, reference will be made throughout this specification to the parent compounds.
Many physiologically active substances elicit their biological actions by interaction with specific sites known as receptors Histamine is such a substance and had a number of 10 biological actions Those biological actions of histamine which are inhibited by drugs commonly called “antihistamines”, of which mepyramine, diphenhydramine and chlorpheniramine are typical examples, are mediated through histamine HIreceptors (Ash and Schild, Brit J Pharmac Chemother, 27, 427, ( 1966)) However, other of the biological actions of histamine are not inhibited by “antihistamines” and actions of this type which are 15 inhibited by a compound described by Black et al (Nature, 236, 385 ( 1972) ) and called burimamide are mediated through receptors which are defined by Black et al as histamine H 2-receptors Thus histamine H 2-receptors may be defined as those histamine receptors which are not blocked by mepyramine but are blocked by burimamide Compounds which block histamine H 2-receptors are referred to as histamine H 2-receptor antagonists 20 Blockade of histamine H 2-receptors is of utility in inhibiting the biological actions of histamine which are not inhibited by “antihistamines” Histamine H 2receptor antagonists are therefore useful, for example, as inhibitors of gastric acid secretion, as anti- inflammatory agents and as agents which act on the cardiovascular system, for example as inhibitors of the effects of histamine on blood pressure In the treatment of certain 25 conditions, for example inflammation and in inhibiting the actions of histamine on blood pressure, a combination of histamine H 1-and H 2-receptor antagonists is useful.
The compounds of this invention are histamine H 2-receptor antagonists In U K Patent Specification No 1421999 we describe and claim sulphoxides of Formula 1:
30 0 E Het-(CH 2)m S(CH 2),NHC> NHR, 35 1 565 205 Formula 1 wherein Het is a 5 or 6 membered heterocyclic ring such as imidazole, pyridine, thiazole, isothiazole, oxazole, isoxazole, pyrazole, triazole, thiadiazole, pyrimidine, pyrazine or pyridazine, which ring is optionally substituted by lower alkyl, trifluoromethyl, hydroxyl, halogen or amino; m is 1 or 2, N is 2 or 3 and the sum of m and N is 3 or 4; E is oxygen, 5 sulphur or NR 2; R 1 is hydrogen or lower alkyl; and R 2 is hydrogen, nitro, cyano, alkanesulphonyl or arenesulphonyl.
We have now found that certain other sulphoxide compounds not covered by Formula 1 are useful in the antagonism of histamine H 2-receptors in the animal body and it is to these compounds that the present invention relates 10 Accordingly we provide compounds of the following Formula 2:
O X II II Het-CH 2 S(CH 2)2 NHCNH(CH 2)2 ZCH 2-Het’ 15 Formula 2 wherein Het and Het’ are each selected from imidazole optionally substituted by methyl or bromo, pyridine optionally substituted by methoxy, hydroxy, chlorine or bromine, thiazole 20 and isothiazole; Z is sulphur, SO or methylene; and X is sulphur, CHNO 2 or NCN.
Throughout the present specification, by the terms “lower alkyl” and “lower alkoxy” we mean alkyl and alkoxy groups containing from 1 to 4 carbon atoms, respectively It will be understood that the structure illustrated in Formula 2 is only one of several possible representations and that other tautomeric forms are also covered by the present invention 25 Hydrates, pharmaceutically acceptable salts and hydrated pharmaceutically acceptable salts of compounds of Formula 2 are also covered by the present invention.
Preferably Het and Het’ are selected from 5-methyl-4-imidazolyl, 5-bromo4-imidazolyl, 3-methoxy-2-pyridyl, 3-hydroxy-2-pyridyl, 3-chloro-2-pyridyl, 3-bromo-2- pyridyl, 2- thiazolyl and 3-isothiazolyl 30 Preferably Het and Het’ are identical.
Preferably Z is sulphur or methylene, particularly preferably sulphur.
Preferably X is CHNO, or NCN.
Specific compounds within the scope of the present invention are 1-nitro-2-l 2-(( 2-thiazolyl)methylsulphinyl)ethylaminol-2-l 2-(( 2 35 thiazolyl)methylthio)ethylaminolethylene and 1-nitro-2 2-bis-l 2-(( 2thiazolyl)methylsulphinyl)ethylaminol-ethylene.
The compounds of the present invention can be produced by a process which comprises the step of reacting a compound of the Formula 3: 40 Het-CH 2 S(CH 2)2 NHQ Formula 3 wherein Het has the same significance as in Formula 2 and Q is hydrogen or, when X is CHNO 2 or NCN, -CX NH(CH,)2 ZCH, Het’ (where Het’ and Z have the same 45 significance as in Formula 2) with a suitable oxidising agent Suitable oxidising agents include peroxybenzoic acid, substituted peroxybenzoic acids such as m- chloroperoxybenzoic acid, peroxyacetic acid and periodates (metaperiodates) such as sodium metaperiodate A preferred oxidising agent is sodium metaperiodate We have found that hydrogen peroxide is not a suitable oxidising agent for the preparation of 50 compounds of Formula 2 wherein X is sulphur.
Preferably the oxidation is carried out in water or an aqueous solution of a water-miscible polar solvent, such as aqueous acetone.
Preferably the oxidation is carried out at between O C and 30 C.
Preferably compounds of Formula 2 wherein Z is sulphur are prepared by oxidising a 55 compound of Formula 3 wherein Q is hydrogen, and converting this aminesulphoxide into a compound of Formula 2 by one of the methods described below Compounds of Formula 2 wherein Z is sulphur and Het and Het’ are identical can be prepared by oxidising a compound of Formula 3 wherein Q is -CXNH(CH 2)2 SCH 2 Het’ under controlled conditions, e g, using only one equivalent of oxidising agent Conversely, when it is 60 required to produce a compound having two sulphoxide groups this restriction will not of course be necessary and 2 equivalents or oxidising agent can be used.
When Q is hydrogen the product of this oxidation is an aminesulphoxide of Formula 4:
3 1 565 205 3 Het CH 2 S(CH 2)2 NH 2 Formula 4 5 wherein Het has the same significance as in Formula 2, and this aminesulphoxide can be converted into a compound of Formula 2 by one of the following series of reactions (outlined in Scheme l):
SCHEME 1 0 X 2 I II l A Het-CH 2 S(CH)2)NH 2 + ASCNHCH 2 Z(CH 2):Het’Formula 4 Formula 5 0 X II Ii Het CH 2 S(CH 2)2 NHCNH(CH 2)2 ZCH 2 Het’ A Formula 2 l B Het-CH 2 S(CH 2)2 NH 2 Formula 4 C 52 and S-alkylation 0 ll (AS)2 C=X or 1 CHet-CH 2 S(CH 2)2 NH 2) (ASO)(AS)C=NO 2 O X Het CH 2 S(CH 2)2 NHCSA Formula 7 ) Lo .a C)l L 4 0 n 0 o 1 565 205 (a) The aminesulphoxide of Formula 4 can be reacted with an isothiourea of Formula 5:
X AS-I NH(CH 2)2 ZCH 2-Het’ 5 Formula 5 wherein Het’, Z and X have the same significance as in Formula 2 and A is lower alkyl, such as methyl These isothioureas of Formula 5 are known compounds, the preparation of 10 which is described for example in British Patent specifications No 1338169, 1397436,
1398426, 1421792 and 1431589 German Offenlegungschrift 2528639.
(b) When X is sulphur the aminesulphoxide of Formula 4 can be reacted with carbon disulphide, and the resultant dithiocarbamate alkylated and reacted with an amine of Formula 6: 15 H 2 N(CH 2)2 ZCH 2 Het’ Formula 6 20 wherein Z and Het’ have the same significance as in Formula 2, to give a compound of Formula 2.
(c) When X is CHNO 2 or NCN the aminesulphoxide of Formula 4 can be reacted under suitable conditions with a compound of formula (AS)2 C=X wherein A is lower alkyl, preferably methyl, to give a compound of Formula 7 (see scheme 1) which is reacted with an 25 amine of Formula 6 to give a compound of Formula 2.
(d) When X is CHNO 2 the amine sulphoxide of Formula 4 can be reacted with 1-alkylsulphinyl-1-alkylthio-2-nitro-ethylene to give a compound of Formula 7, which is subsequently reacted with an amine of Formula 6 to give a compound of Formula 2.
The starting materials of Formula 3 wherein Q is hydrogen (and the amines of Formula 6) 30 are described for example in British Patent Specification No 1338169.
The starting materials of Formula 3 wherein Q is -CX NH(CH 2)2 ZCH 2 Het’ can be prepared by the general methods outlined above and in Scheme 1 for converting a ammnesulphoxide of Formula 4 into a compound of Formula 2 (by substituting an aminethioether for the amine-sulphoxide of Formula 4) and are described for example in 35 British Patent specifications 1421792 and 1431589 and German Offenlegungschrift 2528639.
The sulphoxides of the present invention find their utility in the inhibition of histamine H 2-receptors in the animal body Although we do not wish to be limited in any way by the following explanation of this utility, we believe that this is partly due to the metabolic reductive conversion of sulphoxides to the corresponding thioether compounds which are 40 potent histamine H 2-receptor antagonists This conversion is thought to occur in the large intestine of the animal where the active reducing agent is probably present in the intestinal bacterial flora Because of this mechanism and the differing partition coefficients of the sulphoxides and the corresponding thioethers the principal histamine H 2receptor antagonism action may be delayed for a considerable time after the administration of the 45 sulphoxides This is a particularly useful effect in many cases and it may be utilised, for example to provide a continuing supply of antagonist to an animal after the effect of an initial dose e g, a compound of the type described in British Patent Specifications Nos.
1421792 and 1431589, has started to decline In this regard it is of course possible to administer the sulphoxides of the present invention at the same time and possibly in 50 combination with the said initial dose.
In addition to the above, certain of the sulphoxides of the present invention, in particular those sulphoxides of Formula 2 wherein Z is sulphur or methylene, have intrinsic activity as histamine H 2-receptor antagonists and for example have been found to inhibit histaminestimulated secretion of gastric acid from the lumen-perfused stomachs of rats anaesthetized 55 with urethane, at doses of from 0 5 to 256 micromoles per kilogram intravenously This procedure is referred to in the above mentioned paper of Ash and Schild The activity of these compounds as histamine H 2-receptor antagonists is also demonstrated by their ability to inhibit other actions of histamine which according, to the above mentioned paper of Ash and Schild, are not mediated by histamine H 1-receptors For example, they inhibit the 60 actions of histamine on the isolated guinea pig atrium and isolated rat uterus.
The compounds of this invention inhibit the basal secretion of gastric acid and also that stimulated by pentagastrin or by food.
In addition, the compounds of this invention with intrinsic activity show antiinflamma- tory activity in conventional tests such as the rat paw oedema test, where the oedema is 65 1 565 205 induced by an irritant The rat paw volume is reduced by subcutaneous injection of doses of a compound of Formula 2 wherein Z is sulphur or methylene In a conventional test, such as the measurement of blood pressure in the anaesthetised rat, the action of the compounds of this invention in inhibiting the vasodilator action of histamine can also be demonstrated.
The level of activity of the compounds of this invention is illustrated by the effective dose 5 producing 50 % inhibition of gastric acid secretion in the anaesthetised rat and the dose producing 50 % inhibition of histamine-induced tachycardia in the isolated guinea pig atrium.
For therapeutic use, the pharmacologically active compounds of the present invention will normally be administered as a pharmaceutical composition comprising as the or an 10 essential active ingredient at least one such compound in the basic form or in the form of a pharmaceutically acceptable acid addition salt and in association with a pharmaceutically acceptable diluent or carrier The invention provides such compositions The addition salts for the compositions include those with hydrochloric, hydrobromic, hydriodic, sulphuric and maleic acids and they can conveniently be formed from the corresponding bases of 15 Formula I by standard procedures, for example by treating the base with an acid in (Cl-4) alkanol or by the use of ion exchange resins to form the required salt either directly from the base or from a different addition salt.
The pharmaceutical carrier employed can be solid or liquid Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and 20 stearic acid Exemplary of liquid carriers are syrup, peanut oil, olive oil and water.
A wide variety of pharmaceutical forms can be employed Thus, if a solid carrier is used, the compositions can be tableted, placed in a hard gelatin capsule in powder or pellet form, or in the form of a troche or lozenge The amount of solid carrier can be varied widely but preferably it will be from 25 mg to 1 g If a liquid carrier is used, the compositions can be in 25 the form of a syrup, emulsion, soft gelatin capsule, an aqueous or non- aqueous liquid suspension and for compounds of Formula 2 wherein Z is S or CH 2 as a sterile injectable liquid contained for example in an ampoule.
The pharmaceutical compositions can be prepared by conventional techniques involving procedures such as mixing, granulating and compressing or dissolving the ingredients as 30 appropriate to the desired form of administration.
Advantageously the composition will be made up in a dosage unit form appropriate to the desired mode of administration, for example as a tablet, capsule, injection soluble or as a cream or ointment for topical application.
The active ingredient will be present in the dosage units in an effective amount to block 35 histamine H 2-receptors in an animal body The route of administration can be oral or in the case of compounds of Formula 2 wherein Z is S or CH 2, parenteral.
Preferably, each dosage unit will contain the active ingredient in an amount of from 50 mg to 250 mg.
The active ingredient will preferably be administered one to six times per day The daily 40 dosage regimen will preferably be from 150 mg to 1500 mg.
The invention is illustrated but in no way limited by the following Examples:- Example 1
1 -Nitro-2-l 2 ( 2-thiazolylmethylthio) ethylaminol-2-l 2 ( 2 45 thiazolylmethylsulphinyl)ethylaminolethylene 1-Nitro-2,2-bis-l 2-( 2-thiazolylmethylthio)ethylaminolethylene ( 4 5 g) was added to a stirred solution of an equivalent amount of sodium metaperiodate ( 2 3 g) in water ( 1600 ml) and the resulting solution was stirred at room temperature for 20 hours Evaporation of the solvent and chromatographic purification of the residue on silica gel gave the title product 50 as an oil The structure of the product was confirmed by the 100 m Hz n m r spectrum in 2 H 6-dimethyl-sulphoxide which showed the following resonances:
thiazole-4-H) quartet at 67 88,67 70) integral 4 0 protons thiazole-5-H) 67 75 and 67 59) (standard) theory 55 4.0 protons.
=CRNO 2 singlet a T 66 59 integral 0 9 protons theory 1 proton 60 thiazole-CH 2-SO quartet at 64 65 and 64 55 integral 1 7 protons theory 2 protons thizaole-CH 2-S singlet at 64 17 integral 0 9 protons theory 1 proton 65 1 565 205 CH 2 N multiplet at 63 7 integral 3 8 protons multilt atheory 4 protons CH 2 N multiplet at 63 5) 5 SOCH 2 CH 2 multiplet at 63 1 integral 1 9 protons theory 2 protons SCH 2 CH 2 triplet at 62 7 integral 2 0 protons theory 2 protons 10 Example 2
1-Nitro-2,2-bis-l 2-( 2-thiazolylmethylsulphinyl)ethylaminol-ethylene 1-Nitro-2,2-bis-l 2-( 2-thiazolylmethylthio)ethylaminol-ethylene ( 4 8 g) was added to a stirred solution of sodium metaperiodate ( 4 58 g) in water ( 1500 ml) and the mixture was 15 stirred at room temperature for 24 hours The mixture was concentrated under reduced pressure and was extracted with chloroform and n-octanol and the aqueous solution was evaporated to a solid which was purified by thick layer chromatography on silica gel, eluting with chloroform/methanol 5:1 to give the title product The 100 m Hz n m r spectrum of the product in 2 H 6-dimethylsulphoxide/deuteriochloroform showed the following resonances: 20 thiazole-4-H) AB quartet at 67 87 and 67 56) integral 4 3 protons thiazole-5-H) theory 4 protons 25 =CHNO 2 singlet at 66 67 integral 1 0 protons theory 1 proton thiazole-CH 2-SO AB quartet at 64 67 integral 4 0 30 protons(reference) 64.50 theory 4 protons CH 2 N + HDO multiplet at 63 7 integral 8 6 protons theory 4 protons 35 SOCH 2-CH 2 multiplet at 63 1 integral 4 2 protons theory 4 protons It was particularly observed that the spectrum contained no peaks corresponding to the 40 thiazole-CH 2-S or S-CH 2-CH 2 peaks found in the spectrum of the mono- sulphinyl product of Example 1.
Example 3
When the following compounds 45 a) N-cyano-N’,N”-bis 2-( ( 5-methyl-4-imidazolyl)methylthio)- ethyllguanidine, b) N-cyano-N’,N”-bis 2-(( 5-bromo-4-imidazolyl)methylthio)- ethyllguanidine, c) N-cyano-N’,N”-bis 2-(( 3-bromo-2-pyridyl)methylthio)-ethyllguanidine, d) N-cyano-N’,N”-bis 2-( 2-pyridylmethylthio)ethyllguanidine, e) N-cyano-N’,N’-bis 2-( 2-thiazolylmethylthio)ethyllguanidine, 50 f) 1-nitro-2,2-bisl 2-(( 3-isothiazolyl)methylthio)ethylaminol-ethylene, are substituted for 1-nitro-2,2-bis-l 2-( 2-thiazolylmethylthio)ethylaminolethylene in the general procedure of Example 1 the following compounds are produced:
a) N-cyano-N’-l 2-(( 5-methyl-4-imidazolyl)methylthio)ethyll-N”-l 2-(( 5methyl-4- imidazolyl)methylsulphinyl)ethyll-guanidine, 55 b) N-cyano-N’-l 2-(( 5-bromo-4-imidazolyl)methylthio)ethylzl-N”-l 2-(( 5- bromo-4imidazolyl)methylsulphinyl)ethyll-guanidine, c) N-cyano-N’-l 2-(( 3-bromo-2-pyridyl)methylthio)ethyll-N”-l 2-(( 3- bromo-2pyridyl)methylsulphinyl)ethyllguanidine, d) N-cyano-N’-l 2-2 pyridylmethylthio)ethyll-N”-l 2-( 2 60 pyridylmethylsulphinyl)ethyl guanidine, e) N-cyano-N’-l 2-( 2-thiazolylmethylthio)ethyll-N”-l 2-( 2thiazolylmethylsulphinyl)ethyllguanidinee f) 1-nitro-2-l 2-( 3-isothiazolylmethylthio)ethylaminol-2-l 2-( 3isothiazolylmethylsulphinyl)ethylaminolethylene 65 1 565 205 Oxidation of the same starting materials by the procedure of Example 2 with two equivalents of sodium metaperiodate yields the corresponding bis sulphinyl guanidine.
Example 4
Oxidation of one portion the following compounds with one equivalent of sodium 5 metaperiodate:- a 3-methoxy-2-( 2-aminoethylthio)methylpyridine, b) 3-hydroxy-2-( 2-aminoethylthio)methylpyridine, c 3-chloro-2-( 2-aminoethylthio)methylpyridine, d) 5-bromo-4-( 2-aminoethylthio)methylimidazole, 10 yields the corresponding ( 2-aminoethylsulphinyl)methyl compounds.
Reaction of a second portion of the same starting materials with 1methylthio-1- methylsulpinyl-2-nitroethylene yields respectively:
a) 1-methylthio-2-nitro-1-l 2-(( 3-methoxy-2-pyridyl)-methylthio) ethylaminolethylene, b) 1-methylthio-2-nitro-1-l 2-(( 3-hydroxy-2-pyridyl)-methylthio) ethylaminolethylene, 15 c) 1-methylthio-2-nitro-1 2-(( 3-chloro-2-pyridyl)-methylthio) ethylaminolethylene and d) 1-methylthio-2-nitro-1 l 2-(( 5-bromo-4-imidazolyl)-methylthio) ethylaminolethylene and treatment of these compounds with the corresponding ( 2- aminoethylsulphinyl)methyl compounds prepared above, the products are respectively:
a) 1-nitro-2-l 2-(( 3-methoxy-2-pyridyl)methylthio)-ethylamino-2-l 2-(( 3methoxy-2 20 pyridyl)methylsulphinyl)-ethylaminolethylene, b) 1-nitro-2-l 2-(( 3-hydroxy-2-pyridyl)methylthio)ethylaminol-2-l 2-()3- hydroxy-2pyridyl)methylsulphinyl)-ethylaminolethylene, c) 1-nitro-2-l 2-(( 3-chloro-2-pyridyl)methylthio)ethylaminol-2-l 2-(( 3- chloro-2pyridyl)methylsulphinyl)-ethylaminolethylene and 25 d) 1-nitro-2-l 2-(( 5-bromo-4-imidazolyl)methylthio)ethylaminol-2-l 2-(( 5-bromo-4imidazolyl)methylsulphinyl)-ethylaminolethylene.
Example 5
Reaction of 3-methoxy-2-( 2-aminoethylsulphinylmethyl)-pyridine with 1methylthio-1 30 methylsulphinyl-2-nitro-ethylene yields 1-methylthio-2-nitro-l-l 2-(( 3- methoxy-2pyridyl)methylsulphinyl)ethylaminolethylene which, when reacted with 4-( 4- aminobutyl)imidazole yields 1-nitro-2-l 2-(( 3-methoxy-2pyridyl)methylsulphinyl)ethylamino J-2-l 4-( 4-imidazolyl) butylaminolethylene.
35 Example 6
Oxidation of 5-methyl-4-( 2-aminoethylthio)methylimidazole with one equivalent of sodium metaperiodate yields 5-methyl-4-( 2-aminoethylsulphinyl) methylimidazole and reac- tion of this compound with carbon disulphide gives N-l 2-(( 5-methyl-4imidazolyl)methylsulphinyl)ethylldithiocarbamic acid which, on treatment with methyl 40 iodide may be converted into S-methyl-N-l 2-(( 5-methyl-4-imidazolyl) methylsulphinyl)- ethylldithiocarbamate hydriodide.
Reaction of the latter compound with 5-methyl-4-( 2-aminoethylthio) methylimidazole results in the production of N-l 2-(( 5-methyl-4-imidazolyl) methylsulphinyl)ethyll-N’-l 2-(( 5methyl-4-imidazolyl)methylthio)ethyllthiourea 45 Example 7
Pharmaceutical composition:- 1-Nitro-2-l 2-( 2-thiazolylmethylthio)ethylaminol-2-l 2-( 2thiazolylmethylsulphinyl)ethylaminolethylene 150 mg 50 Sucrose 75 mg Starch 25 mg Talc 5 mg Stearic Acid 2 mg 55 The ingredients are screened, mixed and filled into a hard gelatin capsule.
Example 8
Pharmaceutical composition:- 1-Nitro-2-l 2-( 2-thiazolylmethylthio)ethylaminol-2-l 2 60 ( 2-thiazolylmethylsulphinyl)ethylaminolethylene 200 mg Lactose 100 mg The ingredients are screened, mixed and filled into a hard gelatin capsule.

GB31969/75A
1974-01-15
1975-07-31
Heterocyclic sulphoxides

Expired

GB1565205A
(en)

Priority Applications (30)

Application Number
Priority Date
Filing Date
Title

GB31969/75A

GB1565205A
(en)

1975-07-31
1975-07-31
Heterocyclic sulphoxides

ZA763837A

ZA763837B
(en)

1975-07-31
1976-06-28
Pharmacologically active compounds

IN1187/CAL/76A

IN146152B
(en)

1975-07-31
1976-07-05

DK316076A

DK316076A
(en)

1975-07-31
1976-07-13

HISTAMIN H2 ANTAGONISTS

US05/704,871

US4038408A
(en)

1975-07-31
1976-07-13
Certain thiazolyl and isothiazolyl compounds and compositions and methods which employ them

CS764840A

CS203102B2
(en)

1975-07-31
1976-07-21
Process for preparing thiazolyl compounds

CA257,550A

CA1069904A
(en)

1975-07-31
1976-07-22
Pharmacologically active sulfoxide derivatives

ZM97/76A

ZM9776A1
(en)

1975-07-31
1976-07-23
Pharmacologically active compounds

BE169227A

BE844503R
(en)

1975-07-31
1976-07-23

SULFOXIDES

GR51357A

GR60853B7
(en)

1974-01-15
1976-07-27
Preparation process of pharmacologically active compounds

FR7622849A

FR2361881A2
(en)

1975-07-31
1976-07-27

NEW SULFOXIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATION

SE7608476A

SE7608476L
(en)

1975-07-31
1976-07-27

PHARMACOLOGICAL ASSOCIATIONS

LU75493A

LU75493A1
(en)

1975-07-31
1976-07-29

DD194123A

DD126081A5
(en)

1975-07-31
1976-07-29

CH978476A

CH609683A5
(en)

1975-07-31
1976-07-30

BG7633886A

BG27361A3
(en)

1975-07-31
1976-07-30
Method of obtaining of substituted carbamide derivatives

ES450318A

ES450318A2
(en)

1974-02-08
1976-07-30
Procedure for the production of sulfoxides. (Machine-translation by Google Translate, not legally binding)

NO762660A

NO762660L
(en)

1975-07-31
1976-07-30

FI762192A

FI762192A
(en)

1975-07-31
1976-07-30

SU762386216A

SU618044A3
(en)

1975-07-31
1976-07-30
Method of obtaining thiazole derivatives

DE19762634432

DE2634432A1
(en)

1975-07-31
1976-07-30

SULFOXIDE, THEIR SALT WITH ACIDS, THE PROCESS FOR THEIR PRODUCTION AND THE MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS

NL7608491A

NL7608491A
(en)

1975-07-31
1976-07-30

METHOD FOR PREPARING MEDICINAL PRODUCTS AND PHARMACOLOGICALLY ACTIVE COMPOUNDS.

JP51092244A

JPS5219662A
(en)

1975-07-31
1976-07-30
Heterocyclic compound

AR264158A

AR216056A1
(en)

1975-07-31
1976-07-30

PROCEDURE FOR THE PREPARATION OF 1-NITRO-2,2-BIS- (2- (2-THIAZOLYLMETHYLSULFINYL) -ETHYLAMINE) -ETHYLENE AND 1-NITRO-2- (2- (2-THIAZOLYLMETHYLTHE) -ETHYLAMINE) -2- ( 2-THIAZOLYLMETHYLSULFINYL) -ETHYLAMINO) -ETHYLENE

HU76SI1530A

HU173928B
(en)

1975-07-31
1976-07-30
Process for preparing pharmaceutically active sulfoxide derivatives

PL19153576A

PL191535A1
(en)

1975-07-31
1976-07-30

METHOD OF MAKING PHARMACOLOGICALLY ACTIVE COMPOUNDS

AU16454/76A

AU1645476A
(en)

1975-07-31
1976-07-30
Heterocyclic methyl sulfinyl alkyl guanidines & derivatives

OA55902A

OA05404A
(en)

1975-07-31
1976-07-31

Process for the preparation of pharmacologically active compounds.

RO87166A

RO70855B
(en)

1975-07-31
1976-07-31
Process for preparing pharmacologically active sulphoxides

US05/787,245

US4105770A
(en)

1975-07-31
1977-04-13
Heterocyclomethylsulphinylethyl derivatives of N-cyanoguanidines, thioureas and 2-amino-1-nitroethylene

Applications Claiming Priority (1)

Application Number
Priority Date
Filing Date
Title

GB31969/75A

GB1565205A
(en)

1975-07-31
1975-07-31
Heterocyclic sulphoxides

Publications (1)

Publication Number
Publication Date

GB1565205A
true

GB1565205A
(en)

1980-04-16

Family
ID=10331088
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

GB31969/75A
Expired

GB1565205A
(en)

1974-01-15
1975-07-31
Heterocyclic sulphoxides

Country Status (28)

Country
Link

US
(1)

US4038408A
(en)

JP
(1)

JPS5219662A
(en)

AR
(1)

AR216056A1
(en)

AU
(1)

AU1645476A
(en)

BE
(1)

BE844503R
(en)

BG
(1)

BG27361A3
(en)

CA
(1)

CA1069904A
(en)

CH
(1)

CH609683A5
(en)

CS
(1)

CS203102B2
(en)

DD
(1)

DD126081A5
(en)

DE
(1)

DE2634432A1
(en)

DK
(1)

DK316076A
(en)

ES
(1)

ES450318A2
(en)

FI
(1)

FI762192A
(en)

FR
(1)

FR2361881A2
(en)

GB
(1)

GB1565205A
(en)

HU
(1)

HU173928B
(en)

IN
(1)

IN146152B
(en)

LU
(1)

LU75493A1
(en)

NL
(1)

NL7608491A
(en)

NO
(1)

NO762660L
(en)

OA
(1)

OA05404A
(en)

PL
(1)

PL191535A1
(en)

RO
(1)

RO70855B
(en)

SE
(1)

SE7608476L
(en)

SU
(1)

SU618044A3
(en)

ZA
(1)

ZA763837B
(en)

ZM
(1)

ZM9776A1
(en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4151289A
(en)

1975-01-22
1979-04-24
Smith Kline & French Laboratories Limited
Nitromethylene amidino derivatives containing imidazole groups

US4165378A
(en)

1977-04-20
1979-08-21
Ici Americas Inc.
Guanidine derivatives of imidazoles and thiazoles

IE47044B1
(en)

1977-04-20
1983-12-14
Ici Ltd
Guanidine derivatives

DE2817078C2
(en)

1977-04-20
1995-06-14
Zeneca Ltd

Guanidine derivatives

US4233302A
(en)

1977-12-23
1980-11-11
Glaxo Group Limited
Amine derivatives and pharmaceutical compositions containing them

EP0014057B1
(en)

1979-01-18
1985-01-02
Imperial Chemical Industries Plc
Guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them

US4220654A
(en)

1979-06-04
1980-09-02
Merck & Co., Inc.
Cyclic imidazole cyanoguanidines

US20230349922A1
(en)

2020-08-11
2023-11-02
Université De Strasbourg
H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

GB1421999A
(en)

1973-02-08
1976-01-21
Smith Kline French Lab
Heterocyclic containing sulphoxides

1975

1975-07-31
GB
GB31969/75A
patent/GB1565205A/en
not_active
Expired

1976

1976-06-28
ZA
ZA763837A
patent/ZA763837B/en
unknown

1976-07-05
IN
IN1187/CAL/76A
patent/IN146152B/en
unknown

1976-07-13
US
US05/704,871
patent/US4038408A/en
not_active
Expired – Lifetime

1976-07-13
DK
DK316076A
patent/DK316076A/en
unknown

1976-07-21
CS
CS764840A
patent/CS203102B2/en
unknown

1976-07-22
CA
CA257,550A
patent/CA1069904A/en
not_active
Expired

1976-07-23
BE
BE169227A
patent/BE844503R/en
active

1976-07-23
ZM
ZM97/76A
patent/ZM9776A1/en
unknown

1976-07-27
FR
FR7622849A
patent/FR2361881A2/en
active
Granted

1976-07-27
SE
SE7608476A
patent/SE7608476L/en
unknown

1976-07-29
DD
DD194123A
patent/DD126081A5/xx
unknown

1976-07-29
LU
LU75493A
patent/LU75493A1/xx
unknown

1976-07-30
ES
ES450318A
patent/ES450318A2/en
not_active
Expired

1976-07-30
FI
FI762192A
patent/FI762192A/fi
not_active
Application Discontinuation

1976-07-30
SU
SU762386216A
patent/SU618044A3/en
active

1976-07-30
BG
BG7633886A
patent/BG27361A3/en
unknown

1976-07-30
AU
AU16454/76A
patent/AU1645476A/en
not_active
Expired

1976-07-30
HU
HU76SI1530A
patent/HU173928B/en
unknown

1976-07-30
DE
DE19762634432
patent/DE2634432A1/en
not_active
Withdrawn

1976-07-30
NL
NL7608491A
patent/NL7608491A/en
not_active
Application Discontinuation

1976-07-30
CH
CH978476A
patent/CH609683A5/xx
not_active
IP Right Cessation

1976-07-30
JP
JP51092244A
patent/JPS5219662A/en
active
Pending

1976-07-30
PL
PL19153576A
patent/PL191535A1/en
unknown

1976-07-30
AR
AR264158A
patent/AR216056A1/en
active

1976-07-30
NO
NO762660A
patent/NO762660L/no
unknown

1976-07-31
OA
OA55902A
patent/OA05404A/en
unknown

1976-07-31
RO
RO87166A
patent/RO70855B/en
unknown

Also Published As

Publication number
Publication date

CA1069904A
(en)

1980-01-15

AU1645476A
(en)

1978-02-02

OA05404A
(en)

1981-02-28

BG27361A3
(en)

1979-10-12

HU173928B
(en)

1979-09-28

ZA763837B
(en)

1977-05-25

DK316076A
(en)

1977-02-01

RO70855A
(en)

1984-03-15

ZM9776A1
(en)

1977-09-21

RO70855B
(en)

1984-03-31

LU75493A1
(en)

1977-03-03

SU618044A3
(en)

1978-07-30

FI762192A
(en)

1977-02-01

ES450318A2
(en)

1977-10-01

DD126081A5
(en)

1977-06-15

CS203102B2
(en)

1981-02-27

CH609683A5
(en)

1979-03-15

DE2634432A1
(en)

1977-02-10

AR216056A1
(en)

1979-11-30

IN146152B
(en)

1979-03-10

JPS5219662A
(en)

1977-02-15

PL191535A1
(en)

1978-04-10

FR2361881A2
(en)

1978-03-17

US4038408A
(en)

1977-07-26

SE7608476L
(en)

1977-02-01

FR2361881B2
(en)

1979-04-13

NO762660L
(en)

1977-02-01

BE844503R
(en)

1977-01-24

NL7608491A
(en)

1977-02-02

Contact information